On December 17, 2009, BioMS Medical Corp. and a syndicate of investors invested $14 million in Spectral Diagnostics Inc. to advance Toraymyxin™, a treatment for severe sepsis, towards regulatory approval and commercialization in the USA.

For further details, click here.